polypid®, a specialty pharmaceutical company, develops and manufactures products based on its plex™ technology. so far, 70 patients have been treated in clinical trials with polypid’s anti-infection products demonstrating safety and efficacy. polypid is in the process of submitting its lead product for phase-iii trial in the us and eu. plex™ is able to optimize drugs' therapeutic performance and clinical outcomes. plex™-based protected drug reservoir is implanted directly into the body’s target area thus enabling prolonged delivery of drugs, over periods ranging from days to several months. polypid’s pipeline focuses on 3 products: d-plex™ - intended for prevention and treatment of surgical infections caused by bacteria. its effectiveness is currently being tested in patients undergoing open-heart surgery, with a view to preventing infections that may occur following surgery. the product is currently undergoing clinical studies at several medical centers. bonypid®-1000 - designed to e
Company profile
Ticker
PYPD
Exchange
Website
CEO
Amir Weisberg
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
PYPD stock data
Latest filings (excl ownership)
S-8
Registration of securities for employees
6 Mar 24
20-F
2023 FY
Annual report (foreign)
6 Mar 24
6-K
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
14 Feb 24
6-K
PolyPid Announces Enrollment of the 100th Patient in the Ongoing SHIELD II Phase 3 Trial
14 Feb 24
EFFECT
Notice of effectiveness
14 Feb 24
CORRESP
Correspondence with SEC
12 Feb 24
UPLOAD
Letter from SEC
9 Feb 24
F-3
Shelf registration (foreign)
1 Feb 24
D
$35.01 mm in equity / options / securities to be acquired, sold $35.01 mm, 20 investors
22 Jan 24
6-K
PolyPid Announces Private Placement for $16 Million in Gross Proceeds
5 Jan 24
Transcripts
PYPD
Earnings call transcript
2023 Q4
14 Feb 24
PYPD
Earnings call transcript
2023 Q3
8 Nov 23
PYPD
Earnings call transcript
2023 Q2
9 Aug 23
PYPD
Earnings call transcript
2023 Q1
10 May 23
PYPD
Earnings call transcript
2022 Q4
8 Feb 23
PYPD
Earnings call transcript
2022 Q2
11 Aug 22
PYPD
Earnings call transcript
2022 Q1
11 May 22
PYPD
Earnings call transcript
2021 Q4
9 Feb 22
PYPD
Earnings call transcript
2021 Q2
11 Aug 21
PYPD
Earnings call transcript
2021 Q1
12 May 21
Latest ownership filings
SC 13G
Lukach Aharon
17 Apr 24
SC 13G
Nir Yehuda
5 Apr 24
SC 13G
Rosalind Advisors, Inc.
1 Mar 24
SC 13G
Centaurus Investments Ltd
20 Sep 23
SC 13G/A
Aurum Ventures M.K.I. Ltd.
17 May 23
SC 13G/A
Gabriel Capital Management Ltd.
10 Feb 23
SC 13G/A
Aurum Ventures M.K.I. Ltd.
15 Jul 22
SC 13G/A
Aurum Ventures M.K.I. Ltd.
24 Feb 22
SC 13G
Aurum Ventures M.K.I. Ltd.
24 Feb 22
SC 13G/A
Gabriel Capital Management Ltd.
10 Feb 22
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 3 |
Opened positions | 1 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 4.74 mm |
Total shares | 12.51 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Aurum Ventures M.K.I. | 7.84 mm | $3.10 mm |
Centaurus Investments | 4.22 mm | $1.64 mm |
Gabriel Capital Management | 447.91 k | $0.00 |